Liquid Biopsy is a term given to a minimally invasive method of analyzing Tumor cell DNA circulating in the blood. This is a useful and very promising approach and opens new vistas compared to the Biochemical Biomarkers and Tissue Biopsies dependent monitoring of cancer. However, it throws its own challenges too. Circulating Tumor Cell DNA is present in the blood in a very miniscule amount. Cell free DNA (CfDNA) in itself is very small and
At ASCO 2017, the steadily increasing competitive intensity between Lonsurf (TAS-102, Taiho) and Stivarga (regorafenib, Bayer) will be on display . In addition, the I/O agents are reading out both as monotherapy in specific (dMMR/MSI-H) patient segments, as well as in combinations with other cytotoxic and targeted agents in broader patient segments, across treatment lines. Taiho and Elsevier will be communicating significantly on the real-world confirmation of Lonsurf´s RECOURSE trial. Bayer will continue to emphasize on
ASCO 2017 is primarily setting the stage for future as it relates to Prostate Cancer – a large number of presentations are focused on early stage data from new compounds and/or combinations of existing. The truly practice impacting trials such as IMbassador250, ARASENS, PROfound and TRITON3 will be touched upon as it relates to their design and current status. But we will have to wait for future ASCOs for their readouts. The major Prostate Cancer
Colorectal Cancer Diagnostics and monitoring CRC diagnostics and monitoring follows two pronged strategy Diagnostic tools such as Colonoscopy: Specific, Can Remove Polyps and Take Biopsies. Adverse: Can cause perforation, Can miss small adenomas Flexible sigmoidoscopy: Specific, Can Remove Polyps and Take Biopsies. Adverse: Reduced risk of perforation Double-contrast barium enema: Specific Can miss some Adenomas Computer tomographic colonography Lab Diagnosis using Biomarkers such as Fecal Occult Blood Test: Cheap for screening, Non Specific Stool DNA
Digital Health revolution is around the corner and it won’t be long when this technology will start affecting our daily life and the way we consume healthcare products and services. The divide however is still a long one and from a consumer standpoint, there is a lack of understanding of what really entails digital health. This is an information gap which will definitely need to be addressed as more tangible products and solutions are available
There are four areas of innovation that are noticeable both in isolation and how they feed into each other for a transformation in cancer care “Big data” and Bioinformatics – rapidly developing data management systems and analytics e.g. NGS that will enable us to collect, analyze and learn from vast amounts of real-world data – not just the 3% of patients that participate in clinical trials. Outcome –there will be an increasing slicing and dicing(cancer panomics) of